SWEDISH ORPHAN BIOVITRUM AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 281 SEK | +0.07% |
|
+7.66% | +5.24% |
| Sales 2024 * | 24.71B 2.26B 181B | Sales 2025 * | 27.13B 2.48B 199B | Capitalization | 95.5B 8.73B 699B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.39B 310M 24.81B | Net income 2025 * | 4.9B 447M 35.81B | EV / Sales 2024 * | 4.42 x |
| Net Debt 2024 * | 13.66B 1.25B 99.93B | Net Debt 2025 * | 9.46B 865M 69.24B | EV / Sales 2025 * | 3.87 x |
| P/E ratio 2024 * |
28.1
x | P/E ratio 2025 * |
19.8
x | Employees | 1,752 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 50.87% |
More Fundamentals
* Assessed data
More news
Latest transcript on Swedish Orphan Biovitrum AB
More press releases
More news
| 1 day | +0.07% | ||
| 1 week | +7.66% | ||
| Current month | +5.16% | ||
| 1 month | +4.93% | ||
| 3 months | -2.02% | ||
| 6 months | +28.66% | ||
| Current year | +5.24% |
1 week
261.40
289.60
1 month
251.00289.60
Current year
243.20302.00
1 year
197.90302.00
3 years
127.10302.00
5 years
127.10302.00
10 years
65.25302.00
| Managers | Title | Age | Since |
|---|---|---|---|
Guido Oelkers
CEO | Chief Executive Officer | 59 | 21/05/17 |
Henrik Stenqvist
DFI | Director of Finance/CFO | 57 | 19/07/18 |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sven Ullman
BRD | Director/Board Member | 68 | 31/12/20 |
Annette Clancy
CHM | Chairman | 70 | 07/05/14 |
Staffan Schüberg
BRD | Director/Board Member | 55 | 31/12/19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.15% | 233 M€ | +8.82% | ||
| 0.90% | 5 M€ | +8.63% | ||
| 0.69% | 148 M€ | +7.01% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 281 | +0.07% | 1,124,638 |
| 25/04/24 | 280.8 | +5.41% | 1,324,807 |
| 24/04/24 | 266.4 | -0.97% | 886,847 |
| 23/04/24 | 269 | +2.36% | 667,027 |
| 22/04/24 | 262.8 | +0.69% | 414,483 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 04:29 pm
More quotes
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Companyâs product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
Sector
Pharmaceuticals
Calendar
14/05/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
281
SEK
Average target price
317.2
SEK
Spread / Average Target
+12.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.24% | 8.71B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- SOBI Stock
